Cue Biopharma, Inc.CUENASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank40
5Y CAGR-29.0%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-29.0%/yr
Long-term compound
Percentile
P40
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 3.99% |
| 2024 | -11.05% |
| 2023 | 5.76% |
| 2022 | -6.70% |
| 2021 | 23.26% |
| 2020 | 22.04% |
| 2019 | -3.70% |
| 2018 | 51.02% |
| 2017 | 232.29% |
| 2016 | 278.27% |